Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20729579 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL200722 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL26893965 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL91558 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL8304417 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL27043970 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL692637 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL72827 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL13216436 | 0.91 | HSD17B10 (0.45) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL2965236 | 0.91 | HSD17B10 (0.45) | CHRM2CHRM1CHRM3EPHX1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| US-12473285-B2 | DCN-1 modulating compounds and methods of use thereof | CELLARITY, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250257063-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | THAMES PHARMA PARTNERS | 2025-08-14 | — | — | US | disclosed |
| US-20250163057-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | THAMES PHARMA PARTNERS | 2025-05-22 | — | — | US | disclosed |
| WO-2025096956-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | CELLARITY, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-4469448-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20240309020-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2024-09-19 | — | — | US | disclosed |
| US-20040092559-A1 | Bicyclic modulators of androgen receptor function | HAMANN LAWRENCE (US) | 2004-05-13 | — | — | US | disclosed |
| EP-1414795-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040019063-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-29 | — | — | US | disclosed |
| US-6670386-B2 | For therapy of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-30 | — | — | US | disclosed |
| WO-2003096980-A2 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-27 | — | — | WO | disclosed |
| US-20030055094-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2003-03-20 | — | — | US | disclosed |
| WO-2003011824-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-13 | — | — | WO | disclosed |
| EP-0646596-B1 | Nucleic acid binding oligomers having C-branches for therapy and diagnosis | BAYER AG (DE) | 1999-05-26 | — | — | EP | disclosed |
| US-5849893-A | Nucleic acid-binding oligomers possessing C-branching for therapy and diagnostics | BAYER AKTIENGESELLSCHAFT (DE) | 1998-12-15 | — | — | US | disclosed |
| EP-0646596-A1 | Nucleic acid binding oligomers having C-branches for therapy and diagnosis | BAYER AG (DE) | 1995-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019063-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | CHRM2 533/4885CHRM1 537/4885CHRM3 480/4885 |
| US-12473285-B2 | DCN-1 modulating compounds and methods of use thereof | DCUN1D1, DCUN1D2, DCUN1D4 | CHRM2 4323/4885CHRM1 4012/4885CHRM3 4208/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | CHRM2 4858/4885CHRM1 4828/4885CHRM3 4882/4885 |
| US-20030055094-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | CHRM2 636/4885CHRM1 611/4885CHRM3 562/4885 |
| US-20250163057-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | DCUN1D1, DCUN1D2, DCUN1D4 | CHRM2 4323/4885CHRM1 4012/4885CHRM3 4208/4885 |
| US-12459922-B2 | PARP7 inhibitors | PARP1, PARP11, PARP2 | CHRM2 4882/4885CHRM1 4872/4885CHRM3 4861/4885 |
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | CLIC1, HCCS, CNR1 | CHRM2 172/4885CHRM1 143/4885CHRM3 268/4885 |
| US-20250257063-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | DCUN1D1, DCUN1D2, DCUN1D4 | CHRM2 4323/4885CHRM1 4012/4885CHRM3 4208/4885 |
| US-20040092559-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | CHRM2 636/4885CHRM1 611/4885CHRM3 562/4885 |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | CBR1, CLIC1, RER1 | CHRM2 185/4885CHRM1 149/4885CHRM3 217/4885 |
| US-20240309020-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | CHRM2 4884/4885CHRM1 4881/4885CHRM3 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.